A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

NCT05810103 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Advanced Solid Tumors

Interventions

DRUG: DP303c

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.